Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan pediatric formulation extension in PAH (FUTURE 3 Ext)
NCT01338415Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2011
- Primary completion
- Aug 2014
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 18
01
Overview
A Phase 3 trial of bosentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Mar 2011; status: completed.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01338415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01338415.